乳腺癌患者中57-钴-博来霉素的肿瘤摄取情况。

Tumour uptake of 57-cobalt-bleomycin in patients with breast cancer.

作者信息

Pace L, D'Aiuto G, Acampora C, Oliviero P, Botti G, Tatangelo F, Cerra M, Salvatore M

机构信息

Cattedra di Medicina Nucleare, II Facoltà di Medicina, Università Federico II, Napoli, Italy.

出版信息

Eur J Cancer. 1993;29A(2):195-8. doi: 10.1016/0959-8049(93)90173-d.

DOI:10.1016/0959-8049(93)90173-d

PMID:7678495

Abstract

17 patients with breast carcinoma were studied with 57-cobalt-bleomycin scintigraphy. Scans showed increased tumour uptake in all patients. Results expressed as percentage of the injected dose (ID) normalised by the size of the tumour region (% ID/pixel) showed higher tumour uptake in patients with T3-T4 breast carcinomas (n = 5) than in patients with T1-T2 breast cancer (n = 12) (8.4 +/- 0.55 x 10(-3) vs. 5.25 +/- 1.71 x 10(-3)% ID/pixel, respectively, P < 0.05). An inverse correlation between tumour uptake of 57-cobalt-bleomycin and progesterone receptor concentration was also found in all tumours tested (r = -0.60, P < 0.05, n = 10) and was confirmed in the group of patients with T2 breast carcinomas (r = -0.89, P < 0.05, n = 6). We conclude that a quantitative analysis of 57-cobalt-bleomycin uptake can give additional information suitable for the presurgical characterisation of a tumour.

摘要

对17例乳腺癌患者进行了57钴-博来霉素闪烁扫描研究。扫描显示所有患者肿瘤摄取增加。以肿瘤区域大小归一化后的注射剂量百分比（%ID/像素）表示的结果显示，T3 - T4期乳腺癌患者（n = 5）的肿瘤摄取高于T1 - T2期乳腺癌患者（n = 12）（分别为8.4±0.55×10⁻³ 与5.25±1.71×10⁻³ %ID/像素，P < 0.05）。在所有检测的肿瘤中还发现57钴-博来霉素的肿瘤摄取与孕酮受体浓度呈负相关（r = -0.60，P < 0.05，n = 10），并且在T2期乳腺癌患者组中得到证实（r = -0.89，P < 0.05，n = 6）。我们得出结论，对57钴-博来霉素摄取进行定量分析可以提供适用于肿瘤术前特征描述的额外信息。